Publicaciones (87) Publicaciones de Javier Rodríguez Rodríguez

2024

  1. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

  2. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

  3. Survival and safety after neoadjuvant chemotherapy or upfront surgery for locally advanced colon cancer: meta-analysis

    British Journal of Surgery, Vol. 111, Núm. 2

  4. The ELECLA trial: A multicentre randomised control trial on outcomes of neoadjuvant treatment on locally advanced colon cancer

    Colorectal Disease, Vol. 26, Núm. 4, pp. 745-753

2023

  1. "What medical students with better academic results do: a cross-sectional analysis"

    BMC medical education, Vol. 23, Núm. 1, pp. 19

  2. Delays to surgery following chemoradiotherapy lead to poorer oncologic outcomes in patients with localized pancreatic adenocarcinoma

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 8, pp. 428-434

  3. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    Nature Communications, Vol. 14, Núm. 1

  4. Impact of perineural invasion on the outcome of patients with synchronous colorectal liver metastases treated with neoadjuvant chemotherapy and surgery

    Clinical and Translational Oncology, Vol. 25, Núm. 8, pp. 2523-2531

  5. Liver Resection and Transplantation Following Yttrium-90 Radioembolization for Primary Malignant Liver Tumors: A 15-Year Single-Center Experience

    Cancers, Vol. 15, Núm. 3

  6. Predicting Severe Haematological Toxicity in Gastrointestinal Cancer Patients Undergoing 5-FU-Based Chemotherapy: A Bayesian Network Approach

    Cancers, Vol. 15, Núm. 17

  7. Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma

    Pancreatology, Vol. 23, Núm. 4, pp. 411-419

2022

  1. Long-Term Outcome of Critically Ill Advanced Cancer Patients Managed in an Intermediate Care Unit

    Journal of Clinical Medicine, Vol. 11, Núm. 12, pp. 3472

2021

  1. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 6, pp. 779-789

2020

  1. Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 112, Núm. 1, pp. 16-22

  2. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

  3. Phage therapy: Unexpected drawbacks to reach hospitals

    Future Virology, Vol. 14, Núm. 12, pp. 779-782

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  3. Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling

    PLoS ONE, Vol. 14, Núm. 5

  4. Use of machine-learning algorithms in intensified preoperative therapy of pancreatic cancer to predict individual risk of relapse

    Cancers, Vol. 11, Núm. 5